Koninklijke Philips N.V.(PHG)Earnings, Financials & Key Ratios

PHG•NYSE

$28.16

26.5× P/E·Price updated Jul 6, 2026

SectorHealthcare IndustryMedical Devices Sub-IndustryImaging, radiation, and oncology devices

AboutKoninklijke Philips N.V. operates as a health technology company in North America and internationally. It operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. The company provides diagnostic imaging solutions, includes magnetic resonance imaging, computed tomography (CT) systems, X-ray systems, and detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; integrated interventional systems; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. It also offers acute patient management solutions; emergency care solutions; sleep and respiratory care solutions; and electronic medical record and care management solutions. In addition, the company provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding and digital parental solutions; and male grooming and beauty products and solutions. It has a strategic collaboration with Ibex Medical Analytics Ltd. to jointly promote the digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide, as well as a strategic partnership agreement with NICO.LAB. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.Show more

Revenue$17.83B-1.0%
EBITDA$2.55B+32.9%
Net Income$895M+227.5%
EPS (Diluted)0.93+224.0%
Gross Margin45.18%+4.8%
EBITDA Margin14.29%+34.3%
Operating Margin7.98%+172.0%
Net Margin5.02%+228.8%
ROE7.77%+233.4%

PHG Price & Volume

Koninklijke Philips N.V. (PHG) stock price & volume — 10-year historical chart

Loading chart...

Persistent Revenue Contraction Challenges Philips Turnaround Strategy

Investment Thesis • Updated 2026Q1

VerdictNegative

Growth:Contracting

Profitability:Strained

Financial:Strained

Cash Flow:Mixed

Primary Risk:Regulatory and litigation overhang

Key Thesis Takeaways

Philips faces a difficult path to recovery as it struggles with persistent top-line contraction, evidenced by a 3.1% revenue decline in 2026Q1.
While the company attempts to pivot toward high-margin software, elevated R&D spending exceeding $400 million per quarter has yet to yield a clear inflection in growth.
Investors should remain cautious given the significant $9.6 billion in goodwill and the ongoing volatility in earnings caused by non-recurring litigation and restructuring charges.

Verdict Logic

the company's inability to sustain consistent revenue growth, combined with a 25.58 P/E ratio and significant exposure to litigation-related cash outflows, suggests that the current valuation does not adequately reflect the underlying operational risks.

PHG Growth Metrics

Koninklijke Philips N.V. (PHG) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-3.02%

5 Years0.59%

3 Years0.01%

TTM-1.52%

Profit CAGR

10 Years3.33%

5 Years-5.49%

3 Years-

TTM160.72%

EPS CAGR

10 Years3.49%

5 Years-5.44%

3 Years-

TTM152.5%

Return on Capital

10 Years4.42%

5 Years1%

3 Years3.02%

Last Year7.07%

PHG Recent Earnings

Koninklijke Philips N.V. (PHG) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 9/12 qtrs (75%)●Beat Revenue 6/12 qtrs (50%)

Q2 2026Latest

May 6, 2026

Metric

Actual

Est

EPS

$0.27+12.5%

$0.24

Rev

$4.6B+2.2%

$4.5B

Q1 2026

Feb 10, 2026

Metric

Actual

Est

EPS

$0.70+23.9%

$0.56

Rev

$6.1B+3.1%

$5.9B

Q4 2025

Nov 4, 2025

Metric

Actual

Est

EPS

$0.37+0.0%

$0.37

Rev

$5.0B+0.1%

$5.0B

Q3 2025

Jul 29, 2025

Metric

Actual

Est

EPS

$0.41+29.2%

$0.32

Rev

$5.1B+18.7%

$4.3B

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 6, 2026	$0.27vs $0.24+12.5%	$4.6Bvs $4.5B+2.2%
Q1 2026	Feb 10, 2026	$0.70vs $0.56+23.9%	$6.1Bvs $5.9B+3.1%
Q4 2025	Nov 4, 2025	$0.37vs $0.37+0.0%	$5.0Bvs $5.0B+0.1%
Q3 2025	Jul 29, 2025	$0.41vs $0.32+29.2%	$5.1Bvs $4.3B+18.7%

Based on last 12 quarters of dataView full earnings history →

Latest PHG News

Recent stock market news and headlines for Koninklijke Philips N.V. (PHG)

Business Wire·Jun 29, 2026

University Health in San Antonio selects Philips enterprise monitoring platform to transform patient monitoring and advance system-wide standardization as patient volume grows

CAMBRIDGE, Mass. & SAN ANTONIO--(BUSINESS WIRE)--Royal Philips, a global leader in health technology, and University Health in San Antonio today announced a strategic contract to modernize and standardize patient monitoring through Philips' Enterprise Monitoring as a Service (EMaaS) model. The collaboration will transition University Health in San Antonio to a fully integrated Philips monitoring platform environment, supporting clinical workflows, alarm management initiatives and data-driven de.

GlobeNewsWire·Jun 23, 2026

Philips Home Access Expands its Smart Deadbolt Lineup with New Handleset combos for Prime Day

ONTARIO, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Philips Home Access is expanding its smart deadbolt lineup with new Smart Lock & Handleset/Lever Combo options, offering homeowners a more complete way to upgrade both front-door access and entryway design.

Zacks Investment Research·Jun 22, 2026

Royal Philips (PHG) is a Top-Ranked Value Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

GlobeNewsWire·Jun 17, 2026

Philips helps customers rethink flexibility with the IntelliVue Patient Monitor 6000 Series

June 17, 2026 An accessible entry point brings full-powered Philips monitoring, frictionless measurement expansion and scalable connectivity to the healthcare organizations needing it most. Cambridge, Mass.

Peers Comparison

Key metrics vs top competitors for Koninklijke Philips N.V. (PHG)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
PHGKoninklijke Philips N.V.Current	$28.16	$26.81B	26.52	-1.04%	5.02%	7.77%	1.38%
SYKStryker Corporation	$313.38	$120.14B	37.31	11.16%	13.21%	15.1%	—
BSXBoston Scientific Corporation	$44.60	$66.29B	22.99	19.87%	17.23%	14.67%	—
EWEdwards Lifesciences Corporation	$95.18	$54.8B	52.01	11.55%	17.34%	10.54%	—
BAXBaxter International Inc.	$22.58	$11.66B	-12.90	5.72%	-9.7%	-16.5%	—
ZBHZimmer Biomet Holdings, Inc.	$89.76	$17.58B	25.28	7.2%	9.05%	5.77%	—

Compare PHG vs Peers

Koninklijke Philips N.V. (PHG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs SYK

Most directly comparable listed peer for PHG.

Scale Benchmark

vs GE

Larger-name benchmark to compare PHG against a more recognizable public peer.

Peer Set

Compare Top 5

vs SYK, BSX, EW, BAX

Get notified when PHG posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

PHG Frequently Asked Questions

Koninklijke Philips N.V. (PHG) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is Koninklijke Philips N.V.'s revenue?

Koninklijke Philips N.V. (PHG) reported $17.71B in revenue for fiscal year 2025. This represents a 45% decrease from $31.92B in 1996.

How fast is Koninklijke Philips N.V. growing?

Koninklijke Philips N.V. (PHG) saw revenue decline by 1.0% over the past year.

Is PHG profitable?

Yes, Koninklijke Philips N.V. (PHG) is profitable, generating $972.5M in net income for fiscal year 2025 (5.0% net margin).

Dividend & Returns

Does PHG pay dividends?

Yes, Koninklijke Philips N.V. (PHG) pays a dividend with a yield of 1.38%. This makes it attractive for income-focused investors.

What is PHG's return on equity?

Koninklijke Philips N.V. (PHG) has a return on equity (ROE) of 7.8%. This is below average, suggesting room for improvement.

What is Koninklijke Philips N.V.'s free cash flow?

Koninklijke Philips N.V. (PHG) generated $1.91B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in PHG back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →

Quarter

Date

EPS (Act vs Est)

Revenue (Act vs Est)

Q2 2026Latest

May 6, 2026

$0.27vs $0.24+12.5%

$4.6Bvs $4.5B+2.2%

Q1 2026

Feb 10, 2026

$0.70vs $0.56+23.9%

$6.1Bvs $5.9B+3.1%

Q4 2025

Nov 4, 2025

$0.37vs $0.37+0.0%

$5.0Bvs $5.0B+0.1%

Q3 2025

Jul 29, 2025

$0.41vs $0.32+29.2%

$5.1Bvs $4.3B+18.7%

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

PHGKoninklijke Philips N.V.Current

$28.16

$26.81B

26.52

-1.04%

5.02%

7.77%

1.38%

SYKStryker Corporation

$313.38

$120.14B

37.31

11.16%

13.21%

15.1%

—

BSXBoston Scientific Corporation

$44.60

$66.29B

22.99

19.87%

17.23%

14.67%

—

EWEdwards Lifesciences Corporation

$95.18

$54.8B

52.01

11.55%

17.34%

10.54%

—

BAXBaxter International Inc.

$22.58

$11.66B

-12.90

5.72%

-9.7%

-16.5%

—

ZBHZimmer Biomet Holdings, Inc.

$89.76

$17.58B

25.28

7.2%

9.05%

5.77%

—